EXHIBIT 10.1
Confidential treatment has been requested for portions of this Exhibit. The copy
filed herewith omits the information subject to the confidentiality request.
Omissions are designated as [Intentionally Redacted]. A complete version of this
exhibit has been filed separately with the Securities and Exchange Commission.
CONFIDENTIAL
LICENSE AND COLLABORATION AGREEMENT
FOR
D-63153
by and between
Zentaris GmbH
▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇
▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇ ▇▇▇▇
▇▇▇▇▇▇▇
- herein "Zentaris" -
and
Spectrum Pharmaceuticals, Inc.
▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
▇.▇.▇.
- herein "Spectrum" -
WITNESSETH:
Whereas, Zentaris is the owner of certain patents and know-how relating to
a compound known as "D-63153"; and
WHEREAS, Spectrum desires to obtain certain licenses from Zentaris to
develop and commercialize D-63153 under the aforesaid patents and know-how, and
Zentaris is willing to grant to Spectrum such licenses; and
1
NOW, THEREFORE, in consideration of the foregoing, the Parties to this
Agreement do agree as follows.
1. DEFINITIONS
For purposes of this Agreement, the following terms shall have the
following meanings:
1.1 "AFFILIATE" shall mean and include in relation to each Party, any person,
firm, corporation or other entity: (i) if at least fifty percent (50%) of
the voting stock or other equity interest thereof is owned, directly or
indirectly, by that Party; (ii) which owns, directly or indirectly, at
least fifty percent (50%) of the voting stock or other equity interest of
that Party; or (iii) if at least fifty percent (50%) of the voting stock
or other equity interest thereof is owned, directly or indirectly, by a
person, firm, corporation or other entity that owns, directly or
indirectly, at least fifty percent (50%) of the voting stock or other
equity interest of that Party.
1.2 "AGREEMENT" shall mean this agreement and all Exhibits attached hereto,
and the terms "herein", "hereunder", "hereto" and such similar expressions
shall refer to this Agreement.
1.3 "CONFIDENTIAL INFORMATION" shall mean and include all of know-how, data
and information, not in the public domain, relating to D-63153, the
Contract Products, the Indications, or the business, affairs, research and
development activities, results of clinical trials, national and
multinational regulatory proceedings and affairs, finances, plans,
contractual relationships and operations of the Parties.
1.4 "CONTRACT PRODUCTS" shall mean and include all pharmaceutical products,
manufactured by Spectrum hereunder, whether as mono-preparations or
combination-preparations, with the D-63153 as an active ingredient, for
use in the Field, in any form of administration whatsoever.
1.5 "COPYRIGHT" means any copyright, mask work or other right of authorship,
whether registered or unregistered and including any registrations and
applications therefore.
1.6 "D-63153" shall mean the compound described in Exhibit 1.6 hereto, which
may be covered by one or more of Zentaris' Patent Rights as listed in
Exhibit 1.29 for use in the Field.
1.7 "DEVELOPMENT DATA" shall mean reports of clinical studies and all other
documentation containing or embodying any pre-clinical, clinical and
chemistry, manufacturing and controls data relating to the application for
Regulatory Approval for the Contract Products and/or Compound or the use
of Contract Products and/or D-63153 in the Field, including, but not
limited to, registration dossiers.
1.8 "DEVELOPMENT PLANS" shall mean the plans to develop two Indications from
the Initial Indications, such plans describing the development and
commercialization milestones and setting forth estimated timelines to
achieve such milestones, which such milestones and estimated timelines
will be periodically reviewed and updated by the Steering Committee.
2
1.9 "DOMAIN NAME" means any Internet domain name, including top-level Internet
domain names and all lower-level Internet domain names for which such
top-level domains are a root or parent, whether in the form of an address
for use in electronic mail transfer, a Universal Resource Locator, a File
Transfer Protocol location, or other form suitable for specifying the
location of an electronic data file over a distributed computer network.
1.10 "EFFECTIVE DATE" of this Agreement shall mean the date on which this
Agreement is executed by the duly authorized representatives of each of
the Parties hereto.
1.11 "EXPLORATORY DEVELOPMENT PLANS" shall mean the plans for exploratory work
limited to Phase I and Phase IIa studies in all three Initial Indications,
such plans to describe the estimated timelines for completing such
studies, which such estimated timelines will be periodically reviewed and
updated by the Steering Committee.
1.12 "FIELD" shall mean the use of D-63153 and/or Contract Products for all
human uses.
1.13 "FIRST COMMERCIAL SALE" shall mean in relation to each country within the
Territory, first sale by Spectrum or its Affiliates, licensees, or
distributors of any of the Contract Products for use in the Field in that
country, after obtaining all of the applicable Regulatory Approvals.
1.14 "IMPROVEMENTS" to the Contract Products and/or D-63153 shall mean and
include any and all Inventions, and any and all changes, modifications and
amendments to Zentaris' Know-How which: (i) improve the performance or
efficacy of the Contract Products and/or D-63153; (ii) reduce any side
effects, drug interactions or other adverse effects of the Contract
Products and/or D-63153; or (iii) reduce the cost and/or increase the
efficiency or productivity of the manufacturing and production processes
for the Contract Products.
1.15 "INDICATION(s)" shall mean the Initial Indications and all other
indications within the Field.
1.16 "INITIAL INDICATION(s)" shall mean the use of D-63153 and/or Contract
Products for (i) prostate cancer; (ii) benign prostate hyperplasia (BPH);
and (iii) endometriosis.
1.17 "INTELLECTUAL PROPERTY" means, collectively, Trademarks, Patents,
Copyrights, Domain Names, Trade Secrets and any other proprietary,
intellectual property and other rights relating to any or all of the
foregoing anywhere in the world.
1.18 "INVENTIONS" shall mean any new or useful method, process, manufacture,
compound or composition of matter, whether or not patentable or
copyrightable, or any improvement thereof.
1.19 "LHRH PATENTS" shall mean the composition in matter patents regarding
[Intentionally Redacted].
-------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
3
1.20 "NET SALES" shall mean the amount received by Spectrum, its Affiliates,
its sublicensees or distributors on account of sales of a Contract Product
to Third Parties in the Territory, less the following deductions to the
extent actually allowed or specifically allocated to the Contract Product
by the selling party using generally accepted accounting standards:
(i) sales and excise taxes and duties paid or allowed by the selling
party and any other governmental charges imposed upon the
production, importation, use or sale of such Contract Product;
(ii) customary trade, quantity and cash discounts allowed on Contract
Product;
(iii) allowances or credits to customers on account of rejection or return
of Contract Product or on account of retroactive price reductions
affecting such Contract Product;
(iv) freight and insurance costs, if they are included in the selling
price for the Contract Product invoiced to Third Parties, provided
always that such deduction shall not be greater than the balance
between the selling price actually invoiced to the Third Party and
the standard selling price which would have been charged to such
Third Party for such Contract Product exclusive of freight and
insurance in the respective country or in a comparable country.
For the avoidance of doubt, for each Contract Product the Net Sales shall
be calculated only once for the first sale of such Contract Product by
either Spectrum, its Affiliate, its sublicensees or its distributor, as
the case may be, to a Third Party which is neither an Affiliate,
sublicensee or distributor of Spectrum. A sale of Contract Products by
Spectrum, its Affiliate, its sublicensee or its distributor to a
wholesaler shall be regarded as the first sale of the Contract Product for
the purpose of calculating Net Sales.
1.21 "PARTY" or "PARTIES" shall mean Spectrum or Zentaris, or Spectrum and
Zentaris, as the context admits.
1.22 "PATENT" means any patent or patent application, Invention disclosure, and
other rights of Invention worldwide including, but not limited to, any
continuations, continuations-in-part, divisionals, reissues, renewals,
provisional patents, reexamined patents, applications for any of the
foregoing or other applications or patents claiming the benefit of the
filing date of any such application or patent.
1.23 "REGULATORY APPROVALS" shall mean and include all licenses, permits,
authorizations and approvals of, and all registrations, filings and other
notifications to, any governmental agency or department within the
Territory, including, without limitation, the United States Food and Drug
Administration (FDA) necessary or appropriate for the manufacture,
production, distribution, marketing, sale and/or use of the Contract
Products and/or D-63153 within the Field and in the Territory.
1.24 "TERRITORY" shall mean and include the United States, Canada, Mexico and
India.
4
1.25 "THIRD PARTY" shall mean any other party that is independent from Spectrum
and its Affiliates and Zentaris and its Affiliates.
1.26 "TRADE SECRET" means any confidential information and proprietary
information, including any formula, pattern, compilation, program, device,
method, technique, or process, that: (1) derives independent economic
value, actual or potential, from not being generally known to the public
or to other persons who can obtain economic value from its disclosure or
use; and (2) is the subject of efforts to maintain its secrecy.
1.27 "TRADEMARK" means trademark, service ▇▇▇▇ trade dress, trade name, design,
logo, product name and slogan, (whether registered or unregistered, and
including any common law rights, registrations, and applications for
registration for any of the foregoing) and general intangible of like
nature, together with all goodwill related to the foregoing.
1.28 "ZENTARIS' KNOW-HOW" shall mean and include all specifications, results of
clinical trials, technical data and other information relating to the
design, formulation, manufacture, production, quality control, Regulatory
Approvals, distribution, sale and/or use of D-63153 in the Field, to which
Zentaris has rights as at the Effective Date. Without limiting the
generality of the definition set forth in this Section 1.28, the Zentaris
Know-How is described in more detail in Exhibit 1.28 hereto.
1.29 "ZENTARIS' PATENT RIGHTS" shall mean patents, patent applications,
divisions, continuations, continuation-in-part applications, divisionals,
extensions, substitutions, renewals, confirmations, supplementary
protection certificates and reissues that are owned by Zentaris relating
to, embodied in, or associated with the Contract Products and/or D-63153.
Without limiting the generality of the definition set forth in this
Section 1.29, the Zentaris' Patent Rights are listed in more detail in
Exhibit 1.29 hereto.
2. GRANT AND SCOPE OF LICENSE
2.1 Zentaris hereby grants to Spectrum, and Spectrum hereby accepts
(i) an exclusive license as of the Effective Date to use Zentaris'
Patent Rights and Zentaris' Know-How to develop, use, sell, offer
for sale, have sold, import and export, commercialize, and
(ii) a non-exclusive license to use the Zentaris' Patent Rights and
Zentaris' Know-How to make and have made (except in cases where
Zentaris is supplying the finished dosage form of D-63153 and/or
Contract Products to Spectrum)
Contract Products and/or D-63153 in the Field and in the Territory, in
accordance with the terms and conditions, and subject to the limitations
of this Agreement. The license shall include the right to use Zentaris'
Patent Rights and Zentaris' Know-How in conducting research and
development activities with respect to the use of Contract Products and/or
D-63153 in the Field. [Intentionally Redacted].
-------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
5
2.2 Spectrum shall be entitled to sublicense all or any of its rights under
this Agreement to any Affiliate and, in respect of the commercialization
of Contract Products and D-63153, to any Third Party. Spectrum may
sublicense its rights under this Agreement in respect of the development
of Contract Products and D-63153, including activities related to the
obtainment of Regulatory Approvals for Contract Products and D-63153, to
any Third Party only upon prior written consent of Zentaris, which consent
shall not be unreasonably withheld. Any sublicense granted is subject to
the participation payments specified in Section 4.3 below. In case
Spectrum grants sublicenses hereunder, Spectrum always shall secure
appropriate covenants, obligations and rights from any such sublicensee so
as to ensure that such sublicensee is also able to comply with Spectrum's
covenants and obligations hereunder to the extent that Spectrum shall not
be performing such covenants and obligations. Spectrum shall inform
Zentaris of any sublicenses granted hereunder, and provide to Zentaris a
copy of the sublicense agreement concluded with such sublicensee. Zentaris
acknowledges that all and any information provided by Spectrum to Zentaris
under this Section 2.2 will be deemed to be Confidential Information of
Spectrum and will be subject to the terms of Section 12. However, Spectrum
may redact confidential portions of any such sublicense agreement, but
only to the extent that any such redactions do not impair Zentaris'
ability to ensure compliance with the provisions of this Agreement,
including but not limited to the calculation of the participation payments
specified in Section 4.3.
2.3 Subject to Section 2.4 below, Zentaris will not at any time during the
continuance of this Agreement grant to any person, firm, corporation or
entity a license to develop, use, sell, offer for sale or import Contract
Products and/or D - 63153 in the Field and in the Territory.
2.4 The grant of licenses by Zentaris to Spectrum under Section 2.1 hereof
shall not preclude Zentaris and/or its Affiliates from utilizing Zentaris'
Patent Rights and Zentaris' Know-How and any Improvements relating thereto
for the purpose of carrying out by itself or through a University, a
contract research organization or a non-profit organization (provided that
a material transfer agreement is in place to protect any intellectual
property rights generated) any further non-commercial exploratory and
development work relating to D-63153. Other than the limited use described
in this Section 2.4, the license granted to Spectrum under Sections 2.1
and 2.2 shall be exclusive even as to Zentaris.
2.5 In furtherance of the rights and licenses granted by Zentaris to Spectrum
under this Agreement, within thirty (30) days after the Effective Date of
this Agreement, Zentaris shall furnish to Spectrum a data package that
shall include (i) all of the Zentaris' Know-How as well as (ii) any and
all information, including, without limitations data and reports for IND
submission to the FDA, [Intentionally Redacted] has on the Contract
Products and D-63153 to the extent such information is available to
Zentaris and under Zentaris' control [Intentionally Redacted]. Spectrum
shall not use any of the Zentaris' Know-How and [Intentionally Redacted]
furnished by Zentaris under this Section 2.5 for any purpose whatsoever,
except as specifically authorized in this Agreement, or as otherwise
specifically authorized in writing by
-------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
6
Zentaris. In the event that Spectrum reasonably believes that the
Zentaris' Know-How or [Intentionally Redacted] included in the data
package furnished by Zentaris under this Section 2.5 is incomplete,
Spectrum shall provide written notice thereof to Zentaris, and Zentaris
shall furnish corrected copies of such Zentaris' Know-How and
[Intentionally Redacted] within sixty (60) days after receipt of
Spectrum's written notice hereunder. Zentaris shall use its reasonable
endeavors to answer all questions received from Spectrum regarding the
Zentaris' Know-How and [Intentionally Redacted] as soon as reasonably
possible after receipt.
2.6 Zentaris shall execute all documents, give all declarations regarding the
licenses granted hereunder and reasonably cooperate with Spectrum at the
costs of Spectrum to the extent such documents, declarations and/or
cooperation are required for the recordal or registration of the licenses
granted hereunder at the various patent offices in the Territory for the
benefit of Spectrum.
2.7 Without limiting the generality of Section 2 hereof, Spectrum specifically
acknowledges and agrees that the license granted to Spectrum hereunder is
limited to development, use, and commercialization of the Contract
Products and D-63153 in the Field within the Territory, and subject to any
mandatory legal provisions which may apply, Spectrum shall not knowingly
develop, distribute, market, sell or use any of the Contract Products or
D-63153 for any other application or purpose whatsoever, and shall not
actively promote, or solicit orders for the sale of the Contract Products
outside of the Territory, without the prior written authorization of
Zentaris, which Zentaris may grant or withhold in its sole discretion
3. SPECTRUM'S OBLIGATIONS
3.1 Spectrum shall use its commercially reasonable efforts to develop, market
and sell the Contract Products in the Territory in order to maximize the
Net Sales derived from the Contract Products throughout the continuance of
this Agreement. Without limiting the generality of Spectrum's commercially
reasonable efforts obligation under this Section 3.1, Spectrum shall:
(i) apply for all required Regulatory Approvals in the countries within
the Territory following completion of all appropriate clinical
trials;
(ii) make the First Commercial Sale of the Contract Products in each
country following the issuance of the Regulatory Approvals required
for the manufacturing, distribution, marketing, sale and use of the
Contract Products in the respective country and if appropriate, the
completion of reimbursement negotiations; and
(iii) not manufacture, produce, distribute, market or sell any products
which are directly competitive with the Contract Products in any
country within the Territory, to the extent that any such activities
would involve the use of any of Zentaris' Patent Rights, Zentaris'
Know-How or any other Zentaris Confidential Information.
-------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
7
3.2 Notwithstanding Section 15.2 below, in the event that Spectrum materially
breaches any of its obligations under Section 3.1 hereof, and if after
having received written notice of such breach from Zentaris, Spectrum
fails to cure such breach within ninety (90) days after receipt of
Zentaris' notice thereof, Zentaris shall have the right to convert the
exclusive license rights granted to Spectrum in the relevant country and
for the relevant Initial Indication into non-exclusive license rights, by
furnishing written notice thereof to Spectrum and shall be entitled to use
all Development Data generated by Spectrum hereunder for the development
and commercialization of Contract Products and/or D-63153 in the relevant
country.
3.3 After the First Commercial Sale in the Territory, Spectrum shall furnish
Zentaris with quarterly reports of all of Spectrum's sales of Contract
Products under this Agreement. Each such quarterly report shall (i) be
furnished to Zentaris together with payment of royalties in accordance
with Section 4.9 within ninety (90) days after the close of the calendar
quarter to which it corresponds; and (ii) state Spectrum's total sales of
the Contract Products, broken down by country, during the calendar
quarter, the Net Sales derived by Spectrum from such sales, and the
royalties payable by Spectrum to Zentaris with respect to such Net Sales
pursuant to Section 4.5 of this Agreement. In addition, commencing on
first April 1 following the date of the First Commercial Sale in the
Territory, Spectrum shall provide Zentaris on or before April 1 in each
calendar year with a summary of its marketing activities performed in the
major international markets in the previous calendar year and its
marketing plans for that calendar year.
4. PAYMENTS AND ROYALTIES
4.1 In consideration for the rights and licenses granted by Zentaris to
Spectrum under this Agreement, Spectrum shall pay to Zentaris the lump sum
amount of EURO One Million ((euro)1,000,000) in cash payable on the
Effective Date and [Intentionally Redacted] in common stock of Spectrum
(the "Initial Shares") as soon as reasonably practicable after the
Effective Date, but no later than 5 business days thereafter. The number
of shares of common stock of Spectrum that shall constitute the Initial
Shares shall be determined by (i) converting [Intentionally Redacted] to
U.S. dollars at the exchange rate [Intentionally Redacted] as published in
the Wall Street Journal [Intentionally Redacted], and then (ii) dividing
the resulting dollar amount by [Intentionally Redacted] of Spectrum's
common stock, as traded on the NASDAQ, [Intentionally Redacted], as set
forth in the Wall Street Journal [Intentionally Redacted]. The Initial
Shares shall be issued to Zentaris on the Effective Date, but shall be
held by Zentaris and may not be assigned, transferred, sold or otherwise
disposed of by Zentaris (with the exception only of an assignment or
transfer to an Affiliate of Zentaris, provided that such Affiliate agrees
to be bound by the restrictions on transfer of such Initial Shares set
forth or referred to in Sections 4.1 and 13 of this Agreement) until
December 31, 2005. The Initial Shares shall be subject to the restrictions
on resale set forth or referred to in Sections 4.1 and 13 of this
Agreement. To Spectrum's present knowledge, except for the restrictions on
resale set forth or referred to in Sections 4.1 and 13 of this Agreement,
the Shares shall be free of restrictions on transfer after December 31,
2005.
4.2 In addition to the lump sum payment specified in Section 4.1 hereof and as
further consideration for the rights and licenses granted by Zentaris to
Spectrum under this Agreement, Spectrum shall make the following milestone
payments to Zentaris, up to a maximum of [Intentionally Redacted]:
-------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
8
(i) upon completion of the first Phase II study conducted by or on behalf of
Spectrum, its Affiliates or Sublicensees [Intentionally Redacted]
[Intentionally Redacted];
(ii) upon initiation of the first Phase III study conducted by or on behalf
of Spectrum, its Affiliates or sublicensees and after the first patient in
the Phase III trial has been dosed
[Intentionally Redacted];
(iii) after [Intentionally Redacted] of the patients in the Phase III trial have
been dosed
[Intentionally Redacted];
(iv) upon acceptance by the FDA of submission for Regulatory Approval
[Intentionally Redacted];
(v) upon the first grant of Regulatory Approval for marketing for a Contract
Product in the Territory
[Intentionally Redacted];
(vi) upon the first grant of Regulatory Approval for marketing for a product
with D-63153 as an active ingredient in Japan
[Intentionally Redacted].
[Intentionally Redacted].
[Intentionally Redacted].
Spectrum shall inform Zentaris on the occurrence of a milestone event as
soon as possible, however, not later than within fourteen (14) days
following the occurrence of such milestone event. Milestone payments are
payable within thirty (30) days after Spectrum's receipt of an invoice
issued by Zentaris for such milestone payment.
4.3 In case Spectrum grants sublicenses under Section 2.2 hereof, Spectrum
shall pay to Zentaris [Intentionally Redacted] percent ([Intentionally
Redacted]%) of any lump sum, periodic or other consideration (other than
royalties based on Net Sales) received by Spectrum from sublicensees
including, but not limited to, equity, any upfront fees, sublicense fees,
marketing rights, or other consideration paid for the authorization to use
the Zentaris' Patent Rights and/or Zentaris' Know-How to develop, use,
sell, offer for sale, have sold, import and export, commercialize, make
and have made Contract Products. For the avoidance of doubt, the foregoing
obligation shall not apply in respect of any sums received from
sublicensees on which Spectrum has or is obliged to pay royalties pursuant
to Section 4.5 hereof.
4.4 All fees payable by Spectrum to Zentaris under Sections 4.1, 4.2 and 4.3
hereof are non-refundable upon expiration or termination of this Agreement
for any reason whatsoever assuming such fees have become due during the
term of this Agreement. None of the fees payable by Spectrum to Zentaris
under Sections 4.1, 4.2 and 4.3 may be credited against any of Spectrum's
royalty obligations under Section 4.5 hereof.
4.5 As further consideration for the rights and licenses granted by Zentaris
to Spectrum under this Agreement, Spectrum shall pay royalties to Zentaris
equal to [Intentionally Redacted] percent ([Intentionally Redacted]%) of
Net Sales for annual Net Sales up to [Intentionally Redacted] US dollars
($[Intentionally Redacted]), [Intentionally Redacted]% of Net Sales for
annual Net Sales between [Intentionally Redacted] US dollars
($[Intentionally Redacted]) and [Intentionally Redacted] US dollars
-------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
9
($[Intentionally Redacted]) and [Intentionally Redacted]% of Net Sales for
annual Net Sales exceeding [Intentionally Redacted] US dollars
($[Intentionally Redacted]).
4.6 As consideration for the payment by Spectrum to Zentaris under Section 4.2
(vi), Zentaris shall pay to Spectrum for sales of products with D-63153 as
an active ingredient in Japan either (i) fifty percent (50%) of profits on
sales of products with D-63153 as an active ingredient in Japan, or (ii)
fifty percent (50%) of any lump sum, periodic or other consideration
received by Zentaris from sublicensees including, but not limited to,
royalties, equity, sublicense fees, marketing rights, or other
consideration paid for the authorization to use the Zentaris' Patent
Rights and/or Zentaris' Know-How to develop, use, sell, offer for sale,
have sold, import and export, commercialize, make and have made products
with D-63153 as an active ingredient in Japan. Sections 4.8 et seq. hereof
shall apply mutatis mutandis regarding the payments of Zentaris to
Spectrum under this Section 4.6.
4.7 In the event that a Contract Product is sold in the form of a
combination-preparation for which Spectrum is required to pay a royalty
for an active ingredient to a Third Party (that is not an Affiliate of
Zentaris), the Net Sales attributable to such combination preparation
shall be calculated on a country by country basis by multiplying actual
Net Sales of the combination preparation by the fraction A/(A+B)*C, where
"A" is Spectrum's (or its Affiliates, sublicensees or distributors)
average selling price for D 63153 and "B" is Spectrum's (or its
Affiliates, sublicensees or distributors) average selling price for the
Third Party ingredient(s) when sold in a mono-preparation in the relevant
country during the period to which the Net Sales calculation applies or
the fair market price if sold to an Affiliate and "C" is Spectrum's (or
its Affiliates', sublicensees' or distributors', as applicable) actual Net
Sales of the combination preparation during such period or the fair market
price if sold to an Affiliate.
4.8 Royalty payments shall be made on a country-by-country and a Contract
Product-by-Contract Product basis, however, in countries of the Territory
where the Contract Products are no longer covered by a valid claim of a
Zentaris Patent Right and Spectrum does not have exclusive
commercialization rights in respect of Contract Product as a result of
generic competition by a Third Party (other than an Affiliate or
sublicensee of Spectrum), Spectrum shall not pay any royalties on Net
Sales for such Contract Product in such country, provided that in case of
such generic competition in India the Parties agree to discuss a payment
of royalties for such Contract Product.
4.9 All payments by Spectrum to Zentaris under this Agreement shall be paid in
EURO to the following account:
[Intentionally Redacted]
-------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
10
For purposes of calculating the amounts payable by Spectrum under Sections
4.3 and 4.5 hereof, such payments shall be converted into Euros at the
prevailing open market currency conversion rate (commercial selling rate)
as quoted by the Wall Street Journal fixing rate, issued by Reuters at 3
pm on the last day of the calendar quarter in which such payments were
received by Spectrum.
4.10 Participation payments and royalties under Sections 4.3 and 4.5 shall be
paid on a calendar quarterly basis. Each quarterly payment by Spectrum
under Sections 4.3 and 4.5 shall be paid within ninety (90) days after the
close of the calendar quarter to which it corresponds.
4.11 In the event that any fee payable by Spectrum under Sections 4.1 and 4.2
is not paid to Zentaris on or before the due date therefore, as specified
herein, or any quarterly participation or royalty payment under Sections
4.3 and 4.5 is overdue, the unpaid overdue amount shall bear interest at a
rate equal to three (3) percentage points over LIBOR.
4.12 All payments by Spectrum to Zentaris under this Section 4 shall be paid in
full, without deduction for any sales, use, excise or other similar taxes
which shall be Zentaris' obligation. All payments are exclusive of value
added tax, which shall, if applicable, be invoiced separately. In the
event that Spectrum is required to withhold any taxes on any amount
payable to Zentaris hereunder, under the applicable laws of any country
within the Territory, Spectrum shall at Zentaris' request and cost use its
best efforts to obtain and furnish Zentaris with official tax receipts, or
other evidence of payment of such withholding taxes, sufficient to permit
Zentaris to demonstrate the payment of such withholding taxes, in order to
establish Zentaris' right to a credit for such withholding taxes against
Zentaris' German income tax liability. Spectrum shall provide Zentaris
with all assistance reasonably requested by Zentaris in connection with
any application to any competent tax authorities in any country within the
Territory to qualify for the benefit of a reduced rate of withholding
taxation under any applicable Double Tax Treaty.
4.13 For the term of this Agreement and for a term of three (3) years
thereafter, Spectrum shall maintain complete and accurate books and
records of account, in accordance with generally accepted accounting
principles, of all transactions and other business activities under this
Agreement, sufficient to confirm the accuracy of all reports furnished by
Spectrum to Zentaris under Section 3.3 hereof, and all payments by
Spectrum to Zentaris under this Section 4. Upon reasonable written notice
to Spectrum, Zentaris may request Spectrum's certified public accountant
to audit such books and records of account of Spectrum and to review the
terms of any sublicenses granted by Spectrum, in order to confirm the
accuracy and completeness of all such reports and all such payments.
Zentaris shall bear all costs and expenses incurred in connection with any
such audit. If Zentaris disagrees with the report provided by Spectrum's
accountant, with reasonable justification for such disagreement, then upon
reasonable written notice to Spectrum, a certified public accountant
designated by Zentaris and acceptable to Spectrum shall have the right to
audit such books and records of account of Spectrum and to review the
terms of any sublicenses granted by Spectrum, in order to confirm the
accuracy and completeness of all such reports and all such payments.
Zentaris shall bear all costs and expenses incurred in connection with any
such audit; provided, however, that if any such audit reveals an
11
underpayment of [Intentionally Redacted] percent ([Intentionally
Redacted]%) or more between the amount of payments actually due and the
amount of payments made to Zentaris for the audit period, then, in
addition to paying the full amount of such underpayment, plus accrued
interest, Spectrum shall reimburse Zentaris all such audit costs and
expenses incurred. If the audit reveals an overpayment, Zentaris shall pay
the full amount of the such overpayment to Spectrum.
5. DEVELOPMENT WORK, STEERING COMMITTEE
5.1 Spectrum shall be solely responsible for conducting all necessary research
and development activities (pre-clinical, chemistry, manufacturing and
controls and clinical development) necessary for the Territory and for
bearing all costs and expenses related to such development activities in
accordance with the Exploratory Development Plans and the Development
Plans in order to maximize the commercial potential, if any, of the
Contract Products in the Territory.
5.2 The Steering Committee (defined in Section 5.3 below) shall prepare,
within [Intentionally Redacted] of its formation, three Exploratory
Development Plans for exploratory work limited to Phase I and Phase IIa
studies in all three Initial Indications. At completion of this
exploratory work, the Steering Committee will evaluate the results,
prioritize the Initial Indications and prepare Development Plans, if
scientifically, medically and commercially warranted, for two of the
Initial Indications. The Steering Committee shall have the ability to
review and update any milestones or estimated timelines included in the
Exploratory Development Plans and the Development Plans. Spectrum may
pursue additional indications.
5.3 Immediately after the Effective Date, the Parties shall form a Steering
Committee, which shall be comprised of up to six (6) professionally and
technically qualified representatives, three (3) from each Party. The
Steering Committee shall meet for the first time within four (4) weeks
after the Effective Date, and thereafter as often as necessary, but at
least every calendar half year. The meeting place shall be mutually agreed
to by the Parties. Each Party shall provide the other Party with written
notice of its representatives for the Steering Committee within ten (10)
days after the Effective Date of this Agreement and, thereafter,
immediately upon replacement. The Parties shall be jointly responsible for
directing the activities of the Steering Committee, which activities shall
include but not be limited to the review, validation, modification and/or
update of the Exploratory Development Plans and the Development Plans.
5.4 All decisions of the Steering Committee shall be made in good faith in the
best interest of this Agreement and the Parties shall use their reasonable
efforts to take decisions unanimously. In the event that the Steering
Committee is unable to agree on any matter after good faith attempts to
resolve such disagreement in a commercially reasonable fashion, then the
Chief Executive Officer of Spectrum and the Chairman and Managing Director
of Zentaris shall meet to discuss the matter and
-------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
12
use their best efforts to resolve the matter. If they are unable to do so,
the Chief Executive Officer of Spectrum shall decide the matter.
5.5 Each Party shall keep the other Party informed of relevant or material
development activities performed by it in connection with the development
and commercialization of Contract Products and/or D-63153 and shall
provide the other Party with written notice of all clinical studies,
including any known investigator initiated trials, together with the
results thereof, when available.
6. USE OF DEVELOPMENT DATA
6.1 Subject to Section 6.2 below, each Party will disclose to the other Party
all Development Data, which it generates or which is generated by in
Zentaris' case, its licensees and in Spectrum's case, its sublicensees
during the continuance of this Agreement. Each Party shall be entitled to
disclose such Development Data to in Zentaris' case, its licensees and in
Spectrum's case, its sublicensees. Spectrum shall ensure that its
sublicensees agree to (i) permit Spectrum to disclose their Development
Data to Zentaris and its licensees and (ii) keep confidential all
Development Data disclosed to them pursuant to this Section 6.1. Zentaris
shall ensure that its licensees agree to (i) permit Zentaris to disclose
their Development Data to Spectrum and its sublicensees and (ii) keep
confidential all Development Data disclosed to them pursuant to this
Section 6.1. All Development Data disclosed pursuant to this section shall
be deemed Confidential Information.
6.2 Each Party, licensees and sublicensees (as the case may be) shall be
entitled to use the Development Data disclosed to it pursuant to Section
6.1 for the development and commercialization of D-63153 and/or Contract
Product in accordance with the terms of this Agreement free of charge.
7. IMPROVEMENTS
7.1 Spectrum hereby acknowledges that Zentaris is the owner of all Inventions
and/or Improvements developed by Zentaris and Spectrum shall acquire no
rights, title or interest whatsoever in or to any such Inventions and/or
Improvements, except as specifically provided herein.
7.2 In the event that, during the continuance of this Agreement, Zentaris
develops any Improvements with respect to the use of Contract Products
and/or D-63153 in the Field, Zentaris shall furnish Spectrum with timely
written notice of such Improvements, and shall furnish Spectrum with a
data package which, in Zentaris' reasonable opinion, contains all
information, know-how and other data as Spectrum will require in order to
implement such Improvements. Zentaris shall, and hereby does, grant
Spectrum an exclusive, perpetual, royalty-free license to use all
Improvements and all information, know-how and other data pertaining to
all Improvements furnished by Zentaris to Spectrum hereunder for the
purpose of developing, selling, offering for sale and importing Contract
Products and/or D-63153 in the Field and in the Territory, and subject to
the limitations as provided for in Section 2 above.
13
7.3 Zentaris hereby acknowledges that Spectrum is the owner of all Inventions
and/or Improvements developed by Spectrum and Zentaris shall acquire no
rights, title or interest whatsoever in or to any such Inventions and/or
Improvements, except as specifically provided herein.
7.4 In the event that, during the continuance of this Agreement, Spectrum
develops any Improvements with respect to the use of Contract Products
and/or D-63153 in the Field, Spectrum shall furnish Zentaris with timely
written notice of such Improvements, and shall furnish Zentaris with a
data package which, in Spectrum's reasonable opinion, contains all
information, know-how and other data as Zentaris will require in order to
implement such Improvements in Zentaris' Regulatory Approvals and for
manufacture, production, distribution, marketing, sale and/or use of any
products whatsoever. Spectrum shall, and hereby does, grant Zentaris an
exclusive, worldwide, perpetual, royalty-free license to use all
Improvements and all information, know-how and other data pertaining to
all Improvements furnished by Spectrum to Zentaris hereunder, outside the
Territory and within the Territory outside the Field for any purpose
whatsoever.
7.5 Each Party shall be entitled to disclose all Improvements disclosed to it
by the other Party during the period of this Agreement to, in Zentaris'
case, its licensees and, in Spectrum's case, its sublicensees. During the
term of this Agreement, the use of Zentaris' Improvements by any
sublicensees of Spectrum and the use of Spectrum's Improvements by any
licensee of Zentaris is free of charge. All information regarding such
Improvements and Inventions shall be deemed Confidential Information and
each Party, and each of its licensees, shall keep such information
confidential pursuant to the terms of Section 12.
8. SUPPLY OF D-63153
8.1 Unless Zentaris informs Spectrum that it is no longer willing or able to
supply D-63153 bulk substance, and assuming the API and finished dosage
form manufacturers' continued compliance with cGMP, Spectrum shall
purchase all D-63153 bulk substance and/or finished dosage forms
(collectively referred to "Clinical Supplies") required for development of
Contract Products and/or D-63153 exclusively from Zentaris. Exhibit 8.1
hereto sets forth the specification for the Clinical Supplies (to be
determined within a reasonable time after execution of the Agreement) to
be delivered to Spectrum, and any change of such specifications shall be
agreed between the Parties acting reasonably at least six (6) months prior
to such change becoming effective.
8.2 Spectrum shall at the beginning of each calendar quarter present to
Zentaris a written rolling forecast specifying its estimated demand for
Clinical Supplies for the following twelve (12) months. Any purchase order
by Spectrum shall be firm and binding and not deviate from the quantity
indicated in the rolling forecast by more than [Intentionally Redacted].
Unless otherwise agreed, each quantity of Clinical Supplies ordered by
Spectrum shall be delivered to such address as may be specified by
Spectrum no later than six (6) months following Zentaris' receipt of the
relevant
-------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
14
purchase order. The price for Clinical Supplies will be the actual price
paid by Zentaris for manufacturing and laboratory services including the
price for API, plus a handling and managing surcharge of [Intentionally
Redacted] percent ([Intentionally Redacted]%). However, the price for API
is agreed to be EURO [Intentionally Redacted] ((euro)[Intentionally
Redacted]) per [Intentionally Redacted]. Payment of the purchase price
shall be made within thirty (30) days after the receipt of Zentaris'
invoice.
8.3 If Spectrum discovers any non-conformance of Clinical Supplies with the
agreed terms and specifications as set forth in Exhibit 8.1 hereto, it
shall promptly notify Zentaris of such non-conformance. Spectrum shall
examine each shipment within four (4) weeks from delivery regarding the
conformance with the agreed terms and specifications. In the event
Spectrum does not notify Zentaris of acceptance or rejection within such
four (4) weeks period, the whole shipment is deemed to be accepted, except
for hidden defects, which Spectrum could not reasonably detect. In case of
a non-conformance, Zentaris shall replace at its expense such
non-conforming shipment as soon as possible. Upon Zentaris' request and
expense, Spectrum shall return a non-conforming shipment to the address
stated by Zentaris.
8.4 If, for whatever reason, including a change in the manufacturing process
or the specifications requested by the competent regulatory authorities,
Zentaris is no longer willing or able to ensure Clinical Supply, Zentaris
shall immediately inform Spectrum hereof and Spectrum shall automatically
obtain for the duration of this Agreement a non-exclusive license to use
the Zentaris' Patent Rights and the Zentaris' Know-How to manufacture
and/or have manufactured Clinical Supply for purposes of this Agreement.
8.5 Vials in the possession of Zentaris and available for clinical studies at
the Effective Date will be provided to Spectrum free of charge.
8.6 The supply of a finished dosage form of D-63153 and/or Contract Products
for commercialization will be subject of a separate agreement between the
Parties. The Parties will discuss entering into a joint supply agreement.
If Zentaris is unable or unwilling to supply D-63153 and/or Contract
Products to Spectrum at reasonable terms, including but not limited to
competitive prices, Spectrum shall automatically obtain for the duration
of this Agreement a non-exclusive license to use the Zentaris' Patent
Rights and the Zentaris' Know-How to manufacture and/or have manufactured
the commercial supply for purposes of this Agreement.
8.7 Zentaris shall, at its sole cost and expense, obtain no later than on the
date of first delivery of Clinical Supplies to Spectrum and maintain in
full force and effect during the continuance of this Agreement and
thereafter in accordance with Section 14.7 hereof, usual and customary
commercial general liability insurance, which shall include product
liability coverage.
-------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
15
9. ZENTARIS' PATENT RIGHTS
9.1 Spectrum hereby acknowledges that Zentaris is the owner of all of
Zentaris' Patent Rights and Spectrum shall acquire no rights, title or
interest whatsoever in or to any of Zentaris' Patent Rights, except as
specifically provided in the Agreement. Without limiting the generality of
this Section 9.1, Spectrum shall not utilize any Zentaris' Patent Rights
for any purpose whatsoever, except as specifically authorized in this
Agreement. Spectrum shall not register, or attempt to register, any of
Zentaris' Patent Rights, or otherwise assert any ownership rights with
respect to any of Zentaris' Patent Rights, in any country within the
Territory.
9.2 During the term of this Agreement, Zentaris shall be responsible for
prosecuting the patent applications comprised within the Zentaris' Patent
Rights and for maintaining the patents comprised within the Zentaris
Patent Rights. Spectrum shall at Zentaris' request take such actions, and
shall provide Zentaris with such assistance, as Zentaris shall reasonably
request in order to protect, perfect, maintain and prosecute Zentaris'
rights, title and interests in and to all of Zentaris' Patent Rights
within the Territory. Spectrum shall bear the costs incurred by Zentaris
in relation to prosecution of the patent applications comprised within
Zentaris' Patent Rights and in relation to maintenance of the patents
comprised within Zentaris' Patent Rights, which relate exclusively to
D-63153 in the Territory.
9.3 Zentaris shall keep Spectrum informed and shall consult with Spectrum on
an ongoing basis regarding prosecution of the patent applications and
maintenance of the patents comprised within the Zentaris' Patent Rights
and any actions which require to be taken in relation thereto. Spectrum
shall furnish Zentaris with at least thirty (30) days written notice prior
to the First Commercial Sale of any of the Contract Products in any
country within the Territory, in order to permit Zentaris to take such
action as Zentaris, in its sole discretion, determines to be necessary or
appropriate to protect and perfect Zentaris' rights, title and interests
in and to all of Zentaris' Patent Rights in that country.
9.4 In the event that Zentaris elects not to continue prosecuting or
maintaining any of the Zentaris' Patent Rights, Zentaris shall give to
Spectrum, if possible, sixty (60) days, but in any event not less than
thirty (30) days, written notice before any relevant deadline relating to
or any public disclosure of the relevant Zentaris' Patent Rights. Upon
receipt of a notice from Zentaris indicating that it intends to cease
prosecuting or maintaining any of the Zentaris' Patent Rights, Spectrum
shall have the right to continue, at its own expense, prosecution or
maintenance (as the case may be) of the relevant Zentaris' Patent Rights
and Zentaris shall at the request and cost of Spectrum do all such acts
and execute all such documents as may be necessary to (i) transfer title
to the relevant Zentaris' Patent Rights to Spectrum and (ii) assist
Spectrum with the prosecution and maintenance of the relevant Zentaris'
Patent Rights until such times as Spectrum's title as proprietor of the
relevant Zentaris' Patent Rights has been registered at all of the
appropriate patent offices.
9.5 Each Party shall furnish the other with timely written notice of any and
all infringements and other unauthorized uses by any other person, firm,
corporation or other entity of any of Zentaris' Patent Rights that come to
its attention during the continuance of this Agreement. Zentaris shall be
responsible for taking all actions, in
16
the courts, administrative agencies, or otherwise, including a settlement,
to prevent or enjoin any and all such infringements and other unauthorized
uses of Zentaris' Patent Rights, and Spectrum shall take no action with
respect to any such infringement or unauthorized use of Zentaris' Patent
Rights, without the prior written authorization of Zentaris; provided,
however, that Spectrum shall provide at the request and cost of Zentaris
such assistance as Zentaris shall reasonably request in connection with
any action to prevent or enjoin any such infringement or unauthorized use
of any of Zentaris' Patent Rights. In the event Zentaris is unable or
unwilling to ▇▇▇ the alleged infringer within (i) one hundred twenty (120)
days of the date of notice of such infringement, or (ii) thirty (30) days
before the time limit, if any, set forth in the applicable laws and
regulations for the filing of such actions, whichever comes first, or in
the event Spectrum requires immediate injunctive relief for breach of its
exclusive license and Zentaris, after being informed by Spectrum of the
breach and the proposed action, is unable or unwilling to take such
immediate action, Spectrum may, but shall not be required to take such
action as Spectrum may deem appropriate to prevent or enjoin the alleged
infringement or threatened infringement of a Zentaris' Patent Right. In
such event, Spectrum shall act at its own expense, and Zentaris shall
co-operate reasonably with Spectrum, at the expense of Spectrum, and
Zentaris agrees to be named as a nominal party. In the event of such
action by Spectrum, any recovery obtained shall be paid to Spectrum.
10. JOINT PATENT RIGHTS TO JOINT RESULTS
10.1 All patentable Inventions created, generated, conceived, made, developed,
or reduced to practice jointly by Spectrum and Zentaris (including their
Affiliates or other persons or entities on behalf of Spectrum and
Zentaris) as a result of the work performed under this Agreement shall be
the joint property of Spectrum and Zentaris each of whom shall have a
one-half pro indiviso share. Neither Party shall assign or transfer their
respective shares in any such jointly owned patentable Inventions or in
any patent applications filed therefore or in any patent granted in
respect of any such jointly owned patentable Inventions (all together the
"Joint Patent Rights") to any Third Party without the other Party's prior
written consent.
10.2 The Parties will decide on a case by case basis which Party will have the
responsibility for handling the filing, prosecution and maintenance of any
Joint Patent Rights. Unless agreed otherwise, the Parties will equally
bear the costs of such filing, prosecution and maintenance of Joint Patent
Rights. In making such a decision, the principles observed by the Parties
will be the relative contributions of each Party to the joint Invention,
the standards and customs in the industry and expected efficiency in
patenting procedures.
10.3 Joint Patent Rights shall be filed in the name of both Parties and each
Party shall procure that its respective inventors assign all of their
rights and interests to such Joint Patent Rights to both Parties. Each
Party shall be free to use and exploit the Joint Patent Rights for any
purpose whatsoever. Neither Party shall grant licenses of the Joint Patent
Rights to any Third Party without the other Party's prior written consent
and on terms and conditions to be agreed with the other Party acting
reasonably.
17
10.4 In each case, whichever Party files, prosecutes, and maintains the Joint
Patent Rights ("Prosecuting Party") shall keep the other Party informed of
the filings, prosecution, and maintenance reasonably in advance of any
relevant actions and deadlines to allow for review and consultation. In
the event that the Prosecuting Party elects not to continue prosecuting or
maintaining any of the Joint Patent Rights, the Prosecuting Party shall
give to the other Party, if possible, sixty (60) days, but in any event
not less than thirty (30) days, written notice before any relevant
deadline relating to or any public disclosure of the relevant Joint Patent
Rights. Upon receipt of a notice from the Prosecuting Party indicating
that it intends to cease prosecuting or maintaining any of the Joint
Patent Rights, the other Party shall have the right to continue, at its
own expense, prosecution or maintenance (as the case may be) of the
relevant patent rights and to request the assignment of such right. The
Prosecuting Party shall at the request and cost of the other Party do all
such acts and execute all such documents as may be necessary to assist the
other Party with the prosecution or maintenance of such patent right as
well as with the assignment and transfer of such patent right to the other
Party.
11. EXCHANGE OF SAFETY INFORMATION
11.1 The Parties shall keep each other informed on all reports including
publications of adverse events coming to either Party's knowledge with
regard to Contract Products and/or D-63153, regardless of the origin of
such reports.
11.2 Each Party will report all serious adverse events with a reasonable
suspicion of causal relationship (suspected adverse drug reactions)
occurring in clinical trials under the use of the Contract Products to the
other Party within ten (10) business days after they come to the attention
of that Party. In the event of fatal or life-threatening situations
related to the Contract Products, adverse events will be reported to the
other Party within five (5) business days after they come to the attention
of that Party. Details of an exchange of safety information will be agreed
separately between the Parties after the Effective Date, which agreement
should adhere to the standards required by the appropriate regulatory
agencies.
11.3 Each Party is responsible for submitting its own Periodic Safety Update
Reports in accordance with the applicable guidelines including the "Notice
to Marketing Authorization Holders: Pharmacovigilance Guidelines" and the
ICH E2C Guidelines "Clinical Safety Data Management: Periodic Safety
Update Reports for Marketed Drugs" and will provide a copy of each such
Periodic Safety Update Report to the other Party. When data received from
the other Party might contribute meaningfully to the safety analysis and
influence any proposed or effected changes in the reporting marketing
authorization holder's product information, these data should be included,
with source indicated and discussed in the Periodic Safety Update Reports.
12. CONFIDENTIALITY INFORMATION
12.1 All Confidential Information disclosed, revealed or otherwise made
available by one Party ("Disclosing Party") to the other Party ("Receiving
Party") under, or as a result of, this Agreement is furnished to the
Receiving Party solely to permit the Receiving
18
Party to exercise its rights, and perform its obligations, under this
Agreement. The Receiving Party shall not use any of the Disclosing Party's
Confidential Information for any other purpose, and shall not disclose,
reveal or otherwise make any of the Disclosing Party's Confidential
Information available to any other person, firm, corporation or other
entity, without the prior written authorization of the Disclosing Party.
12.2 In furtherance of the Receiving Party's obligations under Section 12.1
hereof, the Receiving Party shall take all appropriate steps, and shall
implement all appropriate safeguards, to prevent the unauthorized use or
disclosure of any of the Disclosing Party's Confidential Information.
Without limiting the generality of this Section 12.2, the Receiving Party
shall disclose any of the Disclosing Party's Confidential Information only
to those of its officers, employees, agents, consultants, directors,
Licensees, sublicensees, potential sublicensees and financial investors
that have a need to know the Disclosing Party's Confidential Information,
in order for the Receiving Party to exercise its rights and perform its
obligations under this Agreement, and only if such officers, employees,
agents, consultants, directors, Licensees, sublicensees, potential
sublicensees and financial investors have executed appropriate
non-disclosure agreements containing substantially similar terms regarding
confidentiality as those set out in this Agreement or are otherwise bound
by obligations of confidentiality effectively prohibiting the unauthorized
use or disclosure of the Disclosing Party's Confidential Information. The
Receiving Party shall furnish the Disclosing Party with immediate written
notice of any unauthorized use or disclosure of any of the Disclosing
Party's Confidential Information by any officer, employee, agents,
consultants, directors, licensee or sublicensee of the Receiving Party,
and shall take all actions that the Disclosing Party reasonably requests
in order to prevent any further unauthorized use or disclosure of the
Disclosing Party's Confidential Information.
12.3 The Receiving Party's obligations under Sections 12.1 and 12.2 hereof
shall not apply to the extent, but only to the extent, that any of the
Disclosing Party's Confidential Information:
(i) passes into the public domain, or becomes generally available to the
public through no fault of the Receiving Party;
(ii) was known to the Receiving Party prior to disclosure hereunder by
the Disclosing Party;
(iii) is disclosed, revealed or otherwise made available to the Receiving
Party by a Third Party that is under no obligation of non-disclosure
and/or non-use to the Disclosing Party;
(iv) is required to be disclosed under applicable law or by court order,
or in connection with any application by the Receiving Party for any
Regulatory Approvals; provided, however, that the Receiving Party
shall furnish the Disclosing Party's with as much prior written
notice of such disclosure requirement as reasonably practicable, so
as to permit the Disclosing Party, in its sole discretion, to take
appropriate action, including seeking a protective order, in order
to prevent the Disclosing Party's Confidential Information from
passing into the public domain or becoming generally available to
the public; or
19
(v) is independently developed by the Receiving Party without breach of
this Agreement as evidenced by contemporaneous written records.
12.4 Subject to Section 15, upon expiration or termination of this Agreement
for any reason whatsoever, the Receiving Party shall return to the
Disclosing Party, or destroy, as the Disclosing Party shall specify in
writing, all copies of all documents and other materials that contain or
embody any of the Disclosing Party's Confidential Information, except to
the extent that the Receiving Party is required by applicable law to
retain such documents and materials. Within thirty (30) days after the
date of expiration or termination of this Agreement, the Receiving Party
shall furnish the Disclosing Party with a certificate, duly executed by an
officer of the Receiving Party, confirming that the Receiving Party has
complied with it obligations under this Section 12.4.
12.5 All of the Receiving Party's obligations under Sections 12.1 and 12.2
hereof, with respect to the protection of the Disclosing Party's
Confidential Information, shall survive the expiration or termination of
this Agreement for any reason whatsoever.
13. WARRANTIES AND LIABILITIES OF ZENTARIS
Zentaris warrants and represents as follows:
13.1 As of the Effective Date, the LHRH Patents are in compliance with all
legal requirements in the United States regarding the filing, examination,
and maintenance fees. To Zentaris' present knowledge, as of the Effective
Date, all Zentaris Patent Rights are in compliance with all legal
requirements regarding the filing, examination, and maintenance fees. The
above shall not apply to a requirement that, if not satisfied, would not
result in a revocation or lapse or otherwise adversely affect the
enforceability of the patents in question. To Zentaris' present knowledge,
Zentaris has not taken any action or, failed to take any action (including
a failure to disclose material prior art in connection with the
prosecution of any patent), or used or enforced or, failed to use or
enforce any of the Zentaris' Patents Rights in a manner that would result
in the abandonment or unenforceability of any of the Zentaris' Patents
Rights.
13.2 As of the Effective Date, no LHRH Patents have been or are now involved in
any interference, reissue, reexamination or opposing proceeding in the
United States Patent and Trademark Office or any equivalent authority in
Canada. To Zentaris' present knowledge, as of the Effective Date, no
Zentaris Patents Rights have been or are now involved in any interference,
reissue, reexamination or opposing proceeding in any jurisdiction within
the Territory. To Zentaris' present knowledge, no such action has been
threatened. To Zentaris' present knowledge, other than US Patent number
[Intentionally Redacted], there is no patent of any person that claims the
same
-------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
20
subject matter as the LHRH Patents, and Zentaris is not aware of any prior
art that invalidates any claim of any LHRH Patents for use in the Initial
Indications. Spectrum confirms that it is aware of the International
Search Reports issued by the International Searching Authority for
[Intentionally Redacted].
13.3 Zentaris is the owner of all right, title and interest in and to all of
the Zentaris Patents Rights. The LHRH Patents are free and clear of any
and all encumbrances, covenants, conditions and restrictions or, other
adverse claims or interests of any kind or nature, and Zentaris has not
received any written notice or claim or, any oral notice or claim,
challenging Zentaris' complete and exclusive ownership of the LHRH Patents
or suggesting that any other person has any claim of legal or beneficial
ownership with respect thereto, and there is no agreement, decree,
arbitral award or other provision or contingency which obligates Zentaris
to grant licenses in the LHRH Patents. To Zentaris' present knowledge, the
warranties of this Section 13.3 shall also apply to all other Zentaris
Patents Rights.
13.4 To Zentaris' present knowledge, Zentaris owns or possesses adequate
licenses or other rights to use all of the Zentaris' Patents Rights
necessary to develop, make, have made, use, sell, offer for sale, have
sold, import and export and commercialize Contract Products and /or D -
63153 in the Field and in the Territory.
13.5 To Zentaris' present knowledge, the use of the Zentaris' Patents Rights to
develop, make, have made, use, sell, offer for sale, have sold, import and
export and commercialize Contract Products and/or D-63153 in the Field and
in the Territory, would not infringe upon, violate or constitute the
unauthorized use of any rights owned or controlled by any Third Party,
including any Patent of any Third Party. No litigation is now pending and
no notice or other claim has been received by Zentaris, (A) alleging that
Zentaris has engaged in any activity or conduct that infringes upon,
violates or constitutes the unauthorized use of the Patents of any Third
Party, or (B) challenging the ownership, use, validity or enforceability
of the LHRH Patents. To Zentaris' present knowledge, no litigation is now
pending challenging the ownership, use, validity or enforceability of the
Zentaris' Patent Rights.
13.6 To Zentaris' present knowledge, no Third Party is misappropriating,
infringing, diluting or violating any Zentaris' Patent Rights, and no
claims for any of the foregoing have been brought against any Third Party
by Zentaris. Zentaris has taken reasonable steps in accordance with normal
industry practice to protect its Zentaris' Patent Rights.
13.7 Zentaris has experience as an investor in securities of companies and
acknowledges that it can bear the economic risk of its investment in the
Initial Shares and [Intentionally Redacted] issuable to Zentaris pursuant
to the terms of this Agreement. Zentaris either (a) has a pre-existing
personal or business relationship with Spectrum or any of its officers,
directors or controlling persons that is of a nature and duration which
enables Zentaris to be aware of the character, business acumen and general
business and financial circumstances of Spectrum or (b) by reason of its
business or financial expertise or the business or financial experience of
its professional advisors who are unaffiliated with
-------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
21
and who are not compensated by Spectrum or any affiliate or selling agent
of Spectrum, directly or indirectly, has the capacity to protect its own
interests in connection with its acquisition of the Shares. Zentaris is an
"accredited investor" as defined under Rule 501(a) of the Securities Act
of 1933, as amended (the "Securities Act").
13.8 The Shares to be acquired by Zentaris will be acquired for investment for
Zentaris' own account not as a nominee or agent, and not with a view to
the resale or distribution of any part thereof, and Zentaris has no
present intention of selling, granting any participation in, or otherwise
distributing the same. Zentaris does not presently have any contract,
undertaking, agreement or arrangement with any person or entity to sell,
transfer or grant participations to such person or entity or to any third
person or entity, with respect to any of the Shares. Zentaris has not been
formed for the specific purpose of acquiring solely the Shares.
13.9 Zentaris has received and reviewed information about Spectrum and has had
an opportunity to discuss Spectrum's business, management and financial
affairs with its management and to review Spectrum's facilities in order
to reach an informed and knowledgeable decision to acquire the Shares.
Zentaris understands and acknowledges that such discussions, as well as
any written information issued by Spectrum (i) were intended to describe
the aspects of Spectrum's business and prospects which Spectrum believes
to be material, but were not necessarily an exhaustive description, and
(ii) may have contained forward-looking statements involving known and
unknown risks and uncertainties which may cause Spectrum's actual results
in future periods or plans for future periods to differ materially from
what was anticipated and that no representations or warranties were or are
being made with respect to any such forward-looking statements or the
probability of achieving any of the results projected in any of such
forward-looking statements.
13.10 Zentaris understands that the Shares will be issued without registration
under the Securities Act and without qualification and/or registration
under applicable state securities laws ("Blue Sky Laws"), in reliance upon
specific exemptions there from, which exemptions depend upon, among other
things, the bona fide nature of the investment intent and the accuracy of
Zentaris' representations as expressed herein. Zentaris understands that
the Shares are "restricted securities" under applicable U.S. federal and
state securities laws and that, pursuant to these laws, Zentaris must hold
the Shares indefinitely unless they are registered with the SEC and
qualified by state authorities, or an exemption from such registration and
qualification requirements is available. Moreover, Zentaris understands
that Spectrum is under no obligation to register and/or qualify the
Initial Shares. In addition, Zentaris acknowledges that if an exemption
from registration or qualification is available, it may be conditioned on
various requirements including, but not limited to, the time and manner of
sale, the holding period for the Shares, and on requirements relating to
Spectrum which are outside of Zentaris' control, and which Spectrum is
under no obligation and may not be able to satisfy. Zentaris acknowledges
that Spectrum will make a notation on its stock books regarding the
restrictions on transfers set forth in this section and will transfer
securities on the books of Spectrum only to the extent not inconsistent
therewith.
22
13.11 Without in any way limiting the provisions of Section 13.10 above,
Zentaris agrees not to make any disposition of all or any portion of the
Shares unless and until any of the following conditions apply: (a) there
is then in effect a registration statement under the Securities Act
covering such proposed disposition and the disposition is made in
accordance with such registration statement; or (b) (i) Zentaris shall
have notified Spectrum of the proposed disposition and shall have
furnished Spectrum with a statement of the circumstances surrounding the
proposed disposition and (ii) if reasonably requested by Spectrum,
Zentaris shall have furnished Spectrum with an opinion of counsel,
reasonably acceptable to Spectrum, that such disposition will not require
registration under the Securities Act.
13.12 Zentaris understands that the Shares, and any securities issued in respect
of or exchange for the Shares, may bear one or all of the following
legends until they are no longer required by law or the provisions of this
Agreement:
(i) "THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
"SECURITIES ACT"), WITH THE SECURITIES AND EXCHANGE COMMISSION OR
THE SECURITIES COMMISSION OF ANY STATE, AND, ACCORDINGLY, MAY NOT BE
OFFERED, SOLD OR TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN
AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS THEREUNDER
AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES OR BLUE SAY LAWS.
NO HEDGING TRANSACTIONS INVOLVING THESE SECURITIES MAY BE CONDUCTED
EXCEPT IN COMPLIANCE WITH THE SECURITIES ACT."
(ii) Any legend required by the Blue Sky laws of any state to the extent
such laws are applicable to the shares represented by the
certificate so legended.
(iii) The legend set forth above shall be removed by Spectrum from any
certificate evidencing Shares upon transfer of such Shares in
compliance with Rule 144 under the Securities Act or upon delivery
to Spectrum of an opinion, in form and substance and by counsel
reasonably satisfactory to Spectrum, that a registration statement
under the Securities Act is at that time in effect with respect to
the legended security or that such security can be freely
transferred without such a registration statement being in effect
and that such transfer will not jeopardize the exemption or
exemptions from registration pursuant to which the securities were
issued.
13.13 Zentaris acknowledges and agrees that Spectrum makes no representation
with respect to observance of the laws of Zentaris' jurisdiction in
connection with any invitation to subscribe for the Shares, including (i)
the legal requirements within its jurisdiction for the purchase of the
Shares, (ii) any foreign exchange restrictions applicable to such
purchase, (iii) any governmental or other consents that may need to be
obtained, and (iv) the income tax and other tax consequences to Zentaris,
if any, that may be relevant to the purchase, holding, redemption, sale,
or transfer of the Shares, and Zentaris acknowledges and agrees that
Spectrum shall have no responsibility for any
23
effects of such laws on Zentaris as a result of Zentaris' subscription and
payment for and continued beneficial ownership of the Shares.
13.14 Zentaris makes no representation or warranty and specifically disclaims
any guarantee that the development of Contract Products and/or D - 63153
will be successful, in whole or in part, or that the Zentaris' Patent
Rights and Zentaris' Know-How will be suitable for commercialization.
Zentaris expressly disclaims any warranties or conditions, express,
implied, statutory or otherwise with respect to Zentaris' Patent Rights
and Zentaris' Know-How, including without limitation, any warranty or
merchantability of fitness for a particular purpose or non-infringement.
13.15 Zentaris, as a condition to receiving the [Intentionally Redacted], agrees
to provide the above representations and warranties in Sections 13.7
through 13.13 as of the Submission Date.
13.16 Zentaris is a corporation duly organized, validly existing and in good
standing under the laws of its jurisdiction of formation.
13.17 Zentaris has the absolute and unrestricted right, power, authority, and
capacity to execute and deliver this Agreement and to perform its
obligations under this Agreement, which actions have been duly and validly
authorized and approved by all necessary corporate action of Zentaris.
13A. WARRANTIES AND LIABILITIES OF SPECTRUM
Spectrum warrants and represents as follows:
13A.1 Spectrum is aware of the patent USP number [Intentionally Redacted] and
corresponding patents.
13A.2 Spectrum's most recent annual report on Form 10-K and quarterly report on
Form 10-Q as on file with the SEC are accurate and complete in all
material respects and since the date of its most recent Annual Report on
Form 10-K no event has occurred or circumstance existed that has had, or
is reasonably expected to cause, a Material Adverse Effect on Spectrum. A
"Material Adverse Effect" for purposes of this Section 13A means any
effect or change that would be (or could be reasonably expected to be)
materially adverse to the business, assets, financial condition or
operating results of Spectrum, excluding any adverse change, event,
development, or effect arising from or relating to (a) general business or
economic conditions, including such conditions related to the business of
Spectrum, (b) national or international political or social conditions,
including the engagement by the United States in hostilities, whether or
not pursuant to the declaration of a national emergency or war, or the
occurrence of any military or terrorist attack upon the United States, or
any of its territories, possessions, or diplomatic or consular offices or
upon any military installation, equipment or personnel of the United
States, (c) financial, banking, or securities markets (including any
disruption thereof or any decline in the price of
-------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
24
securities generally or any market or index), (d) changes in United States
generally accepted accounting principles, and (e) changes in law, rules,
regulations, orders, or other binding directives issued by any government
entity.
13A.3 Spectrum is a corporation duly organized, validly existing and in good
standing under the laws of its jurisdiction of formation. Spectrum has
full corporate power and authority to conduct its business as it is now
being conducted and to own or use the properties and assets that it
purports to own or use. Spectrum is duly qualified and in good standing to
do business in each jurisdiction in which such qualification is necessary
because of the nature of the business conducted by it except where the
failure to be so qualified would not reasonably be expected to have a
Material Adverse Effect.
13A.4 Spectrum has the absolute and unrestricted right, power, authority, and
capacity to execute and deliver this Agreement and to perform its
obligations under this Agreement, which actions have been duly and validly
authorized and approved by all necessary corporate action of Spectrum.
13A.5 When issued in accordance with the provisions of this Agreement, the
Shares will be duly and validly issued, fully paid, and non-assessable,
and to Spectrum's present knowledge, will be free of restrictions on
transfer other than the restrictions set forth or referred to in Sections
4.1 and 13 of this Agreement.
14. INDEMNIFICATION AND INSURANCE
14.1 Zentaris shall defend, indemnify and hold Spectrum harmless against any
Third Party claims, suits, actions, proceedings, losses, liabilities,
damages, costs and expenses (collectively "Claims and Liabilities")
arising from, related to, or attributable to:
(i) any breach of any of Zentaris' representations, warranties or
covenants set forth in this Agreement; and
(ii) any other negligent, willful or intentionally wrongful act, error or
omission on the part of Zentaris, or any officer, director,
employee, agent or representative of Zentaris.
Zentaris' indemnification obligation under this Section 14.1 shall be
subject to each of the following conditions: (i) Spectrum shall furnish
Zentaris with written notice of any such Claims and Liabilities within
thirty (30) days of the date on which Spectrum receives notice thereof;
(ii) Zentaris shall be solely responsible for the investigation, defense,
settlement and discharge of such Claims and Liabilities (provided that
such settlement does not impose any material obligation on the indemnitee
or the other Party); and (iii) Spectrum shall at Zentaris' cost furnish
Zentaris with all assistance reasonably requested by Zentaris in
connection with the investigation, defense, settlement and discharge of
such Claims and Liabilities. Spectrum's failure to comply with its
obligations pursuant to this Section 14.1 shall not constitute a breach of
this Agreement or relieve Zentaris of its indemnification obligations
pursuant to this Section 14.1, except to the extent, if any, that
Zentaris' defense of the effective claim, action or proceeding actually
was materially impaired thereby.
25
14.2 In the event that it is determined by any court of competent jurisdiction
that Spectrum's use of Zentaris' Patent Rights and/or Zentaris' know-How
Spectrum's use of Zentaris' Patent Rights and/or Zentaris' Know-How in
accordance with the terms and conditions of this Agreement infringes, or
Zentaris reasonably determines that Spectrum's use of Zentaris' Patent
Rights and/or Zentaris' Know-How is likely to infringe any Intellectual
Property Right of a Third Party, Zentaris shall in consultation with
Spectrum use commercially reasonable efforts to (i) procure at Zentaris'
expense a license from such Third Party authorizing Spectrum to continue
to utilize Zentaris' Patent Rights; or (ii) modify the Zentaris' Know-How,
so as to render it non-infringing. In the event that neither of the
foregoing alternatives is reasonably available or commercially feasible,
Spectrum may at its option either cease using the Zentaris' Patent Rights
and/or Zentaris' Know-How for so long as and to the extent that such
Zentaris' Patent Rights and/or Zentaris' Know-How are infringing the
relevant Third Party rights or terminate the rights and licenses granted
to Spectrum solely with respect to that county or those countries in which
the infringement of Third Party rights has occurred or is likely to occur.
14.3 Zentaris' obligations under Sections 14.1 and 14.2 hereof shall not apply
to any allegations of infringement of the intellectual property rights of
another person, firm, corporation or other entity that would not have
arisen but for: (i) Spectrum's use of Zentaris' Patent Rights and/or
Zentaris' Know-How in violation of the terms and conditions of this
Agreement; (ii) any modification, adaptation or application of Zentaris'
Know-How made by Spectrum without the prior authorization of Zentaris; or
(iii) any combination of the Contract Products with any other products,
compounds or materials but only if the allegation of infringement does not
relate to D-63153.
14.4 Spectrum shall defend, indemnify and hold Zentaris harmless against any
and all Claims and Liabilities arising from, related to, or attributable
to:
(i) any claim, including any product liability claim, by any Third Party
with respect to any of the Contract Products regardless of whether
such claim is based on contract, breach of warranty, any form of
tort, strict liability, or otherwise;
(ii) any allegation that any of the Contract Products fail to conform
with the requirements of any applicable laws and/or any applicable
Regulatory Approvals, including, but not limited to, the failure by
Spectrum to obtain any required Regulatory Approvals for the
Contract Products;
(iii) any breach of any of Spectrum's representations, warranties or
covenants set forth in this Agreement; or
(iv) any other negligent, willful or intentionally wrongful act, error or
omission on the part of Spectrum, or any officer, director,
employee, agent or representative of Spectrum.
Spectrum's indemnification obligation under this Section 14.4 shall be
subject to each of the following conditions: (i) Zentaris shall provide
Spectrum with written notice of any such Claims and Liabilities within
thirty (30) days after Zentaris receives notice
26
of such Claims and Liabilities; (ii) subject to Spectrum confirming in
writing that the indemnity will apply to the relevant Claims and
Liabilities, Spectrum shall be solely responsible for the investigation,
defense, settlement and discharge of such Claims and Liabilities (provided
that such settlement does not impose any material obligation on the
indemnitee or the other Party); and (iii) Zentaris shall at Spectrum's
cost furnish Spectrum with all assistance reasonably requested by Spectrum
in connection with the investigation, defense, settlement and discharge of
such Claims and Liabilities. Zentaris' failure to comply with its
obligations pursuant to this Section 14.4 shall not constitute a breach of
this Agreement or relief Spectrum of its indemnification obligations
pursuant to this Section 14.4, except to the extent, if any, that
Spectrum's defense of the effective claim, action or proceeding actually
was materially impaired thereby.
14.5 Spectrum shall, at its sole cost and expense, obtain no later than on the
date of First Commercial Sale of the Contract Products in any country
within the Territory, and shall maintain in full force and effect during
the continuance of this Agreement and thereafter in accordance with
Section 14.7 hereof, usual and customary commercial general liability
insurance, which shall include product liability coverage.
14.6 Spectrum shall, if possible, and, if any additional expense is involved,
subject to reaching agreement with Zentaris' as to which Party shall bear
the costs thereof, cause Zentaris and Zentaris' licensees to be named as
additional insured under Spectrum's commercial general liability insurance
policies under Section 14.5 hereof. Each such commercial general liability
insurance policy obtained and maintained by Spectrum under Section 14.5
shall provide for at least thirty (30) days written notice to Zentaris and
Zentaris' licensors prior to cancellation, non-renewal or material change
in such insurance policy. In the event of cancellation or non-renewal of
any such commercial general liability insurance policy, Spectrum shall, at
its sole cost and expense, obtain replacement insurance coverage, in
accordance with the requirements of Section 14.5 hereof, prior to the
effective date of such cancellation or non-renewal.
14.7 Zentaris' indemnification obligation under Section 14.1 hereof and
Zentaris' obligation to maintain commercial general liability insurance
under Section 8.7 hereof, Spectrum's indemnification obligation under
Section 14.4 hereof, and Spectrum's obligation to maintain commercial
general liability insurance under Section 14.5 hereof, shall survive the
expiration or termination of this Agreement for any reason whatsoever for
a period of five (5) years after the date of expiration or termination
hereof.
14.8 Zentaris' liability in case of simple negligence shall be excluded. Except
in case of willful misconduct, Zentaris shall not be liable to Spectrum
for any indirect, punitive or consequential damages, whether based on
contract or tort, or arising under applicable law or otherwise.
[Intentionally Redacted].
-------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
27
15. TERM AND TERMINATION
15.1 This Agreement shall enter into effect on the Effective Date, and shall
remain in full force and effect for a period of ten (10) years from the
First Commercial Sale of the Contract Products in any country within the
Territory or as long as any Contract Product is covered by a valid claim
of a Zentaris' Patent Right in the Territory, whichever term is longer.
15.2 In the event that either Party (the "Breaching Party") commits a material
breach or default of any of its obligations hereunder, such material
breach to include, but not to be limited to, a material breach of the
obligations under Section 3.1 above, the other Party hereto (the
"Non-Breaching Party") may give the Breaching Party written notice of such
material breach or default, and shall request that such material breach or
default be cured as soon as reasonably practicable. In the event that the
Breaching Party fails to cure such material breach or default within
ninety (90) days after the date of the Non-breaching Party's notice
thereof, the Non-Breaching Party may terminate this Agreement as a whole
or on an Indication-by-Indication basis by giving written notice of
termination to the Breaching Party. Termination of this Agreement in
accordance with this Section 15.2 shall not affect or impair the
Non-Breaching Party's right to pursue any legal remedy, including, but not
limited to, the right to recover damages, for any harm suffered or
incurred by the Non-Breaching Party as a result of such material breach or
default. For purposes of this Agreement, it is not a "material breach" of
this Agreement by Spectrum if the development is delayed due to the
following: (i) scientific, medical or technical reasons; (ii)
circumstances that are beyond the control of Spectrum; or (iii) the fault
of Zentaris.
15.3 In addition to the termination rights provided for in Section 15.2 hereof,
each Party shall have the right to terminate this Agreement, immediately
by giving written notice of termination to the other Party, if the other
Party files a voluntary petition, or if an involuntary petition is granted
in respect of the other Party and appeal proceedings are not commenced
within a period of seven (7) days from the date of such petition under the
bankruptcy provisions of applicable law, or the other Party is declared
insolvent, undergoes voluntary or involuntary dissolution, or makes an
assignment for the benefit of its creditors, or fails or is unable to pay
its debts as they come due, or suffers the appointment of a receiver or
trustee over all, or substantially all, of its assets or properties.
15.4 Notwithstanding any other provision of this Agreement, Spectrum shall have
the right to terminate this Agreement in its entirety or with respect to
any particular Contract Product and/or country in the Territory, at any
time upon sixty (60) days' notice to Zentaris.
15.5 Except as set out in Section 15.10 hereof, immediately upon the expiration
or termination of this Agreement for any reason whatsoever, Spectrum shall
cease all distribution, marketing and sale of the Contract Products under
the licenses granted hereunder; provided, however, that, if this Agreement
is terminated for any reason other than a breach or default hereunder by
Spectrum, Spectrum shall have the right to distribute and sell its
existing inventory of the Contract Products for a period of not more than
one hundred and twenty (120) days following the date of expiration or
termination hereof, subject to Spectrum's continuing obligation to pay
royalties with respect to the Net Sales derived from the distribution and
sale of such existing
28
inventory of the Contract Products, in accordance with the requirements of
Section 4.5 hereof.
15.6 Termination of this Agreement for any reason whatsoever shall not relieve
Spectrum of its obligations: (i) to pay all royalties and other amounts
payable to Zentaris which have accrued prior to, but remain unpaid as of,
the date of expiration or termination hereof, or which accrue thereafter,
in accordance with Section 15.5 hereof; (ii) to defend, indemnify and hold
Zentaris, its licensors and their respective officers, directors,
shareholders, employees, agents and representatives harmless against
claims and liabilities, as provided in Section 14.4 hereof; and (iii) to
maintain commercial general liability insurance coverage, in accordance
with the requirements of Sections 14.5 and 14.6 hereof. In addition,
termination of this Agreement for any reason whatsoever shall not relieve
Zentaris of its obligations (i) to defend, indemnify and hold Spectrum,
its licensors and their respective officers, directors, shareholders,
employees, agents and representatives harmless against claims and
liabilities, as provided in Section 14.1 hereof, or any other surviving
obligations, and (ii) to maintain commercial general liability insurance
coverage, in accordance with the requirements of Section 8.7
15.7 Except in the case of termination of this Agreement by Spectrum under
Sections 15.2 or 15.3, the expiration or termination of this Agreement
shall not adversely affect or impair Zentaris' right to continue to use
any and all Improvements licensed by Spectrum to Zentaris under Section
7.4 hereof. Except as otherwise specifically provided in this Agreement,
upon expiration or termination of this Agreement for any reason
whatsoever, Zentaris shall have no further obligations to Spectrum
hereunder.
15.8 Except in the case of termination of this Agreement by Zentaris under
Sections 15.2 or 15.3, the expiration or termination of this Agreement
shall not adversely affect or impair Spectrum's right to continue to use
any and all Improvements licensed by Zentaris to Spectrum under Section
7.2 hereof. Except as otherwise specifically provided in this Agreement,
upon expiration or termination of this Agreement for any reason
whatsoever, Spectrum shall have no further obligations to Zentaris
hereunder.
15.9 In the event of termination of this Agreement by Zentaris pursuant to
Sections 15.2 or 15.3 or by Spectrum pursuant to Sections 15.4, Zentaris
shall have the right to use all the Development Data in the Field and in
the Territory and to demand from Spectrum the transfer of Regulatory
Approvals for the territory concerned to Zentaris or a person or company
named by Zentaris within ninety (90) days after the termination date
against payment of all external costs which Spectrum incurred in
connection with obtaining the Regulatory Approvals to be transferred. If
Regulatory Approvals have not been obtained by Spectrum, Zentaris may
claim from Spectrum that Spectrum transfers to Zentaris the status of an
applicant for the Regulatory Approvals and notifies the competent
regulatory authority thereof and supplies Zentaris with all documents
already prepared by Spectrum for the filing of applications for Regulatory
Approvals.
15.10 In the event of termination of this Agreement by Spectrum pursuant to
Sections 15.2 or 15.3, the license rights contained in Sections 2.1 and
2.2 shall continue in full force and effect, Spectrum's obligations under
Sections 4 to 10 hereof shall terminate and from the date of such
termination the participation payment and the royalty rates set
29
out in Sections 4.3 and 4.5 will be reduced by [Intentionally Redacted]
percent ([Intentionally Redacted]%).
15.11 Notwithstanding the foregoing, in the event of any termination of this
Agreement by Spectrum pursuant to Sections 15.2 or 15.4 or by Zentaris
pursuant to Section 15.2 with respect to fewer than all of the Contract
Products and/or fewer than all of the countries in the Territory, the
Development Data and/or Regulatory Approvals to be transferred, granted
and otherwise assigned to Zentaris under Section 15.9 shall be expressly
limited to those pertaining to the Contract Products and/or the countries
in the Territory to which such termination applies.
16. GENERAL PROVISIONS
16.1 ASSIGNMENT
Subject to the other terms of this Agreement, neither Party shall have the
right or the power to assign any of its rights, or delegate or subcontract
the performance of any of its obligations under this Agreement, without
the prior written authorization of the other Party, such written
authorization not to be unreasonably withheld or delayed; provided,
however, that the prior written authorization of the other Party shall not
be required for a Party to assign any of its rights, or delegate or
subcontract the performance of any of its obligations hereunder to an
Affiliate or pursuant to a sale of substantially all of the assets of the
Party, merger, consolidation, reorganization or other similar transaction.
Any permitted assignment or delegation hereunder by either Party, whether
to an Affiliate or pursuant to a sale of substantially all of the assets
of the Party, merger, consolidation, reorganization or other similar
transaction pursuant to this Section 16.1, or pursuant to the prior
written authorization of the other Party, shall not relieve such Party of
any of its obligations under this Agreement, including, but not limited
to, the Party's obligation to make royalty payments with respect to any
and all Net Sales derived by any of the Party's assignees or sublicensees
from the distribution, marketing and sale of any of the Contract Products.
16.2 FORCE MAJEURE
Neither Party shall be liable for any failure to perform, or any delay in
the performance of, any of its obligations under this Agreement to the
extent, but only to the extent, that such Party's performance is prevented
by the occurrence of an event of force majeure. For purposes of this
Section 16.2, an event of force majeure shall mean and include, war, civil
war, insurrection, rebellion, civil unrest, fire, flood, earthquake,
adverse weather conditions, strike, lockout, labor unrest, unavailability
of supplies, materials or transportation, acts of the public enemy, acts
of government authorities, and, in general, any other cause or condition
beyond the reasonable control of the party whose performance is affected
thereby. In the event that a Party's performance is affected by the
occurrence of any event of force majeure, that Party shall furnish
immediate written notice thereof to the other Party hereto.
16.3 NOTICES
All notices, reports and other communications between the Parties under
this
-------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
30
Agreement shall be sent by registered air mail, postage prepaid and return
receipt requested, by international air courier, or by facsimile, with a
confirmation copy sent by registered air mail or international air
courier, addressed as follows:
To: Zentaris Zentaris GmbH
▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇
▇-▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇/▇▇▇▇
▇▇▇▇▇▇▇
Attention:________________________
Facsimile:________________________
To: Spectrum Spectrum Pharmaceuticals, Inc.
▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇, M.D.
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
16.4 GOVERNING LAW, JURISDICTION
This Agreement shall be governed by, and interpreted in accordance with
the laws of Switzerland, without reference to conflicts of laws
principles. The United Nations Conventions on Contracts for the
International Sale of Goods shall not be applicable to this Agreement. The
validity of the intellectual property rights shall be subject to an
evaluation under the law of the country in which the intellectual property
rights were applied for or have been issued. Exclusive jurisdiction shall
vest with the Geneva courts.
16.5 SEVERABILITY
If any provision of this Agreement is determined by any court or
administrative tribunal of competent jurisdiction to be invalid or
unenforceable, the Parties shall negotiate in good faith a replacement
provision that is commercially equivalent, to the maximum extent permitted
by applicable law, to such invalid or unenforceable provision. The
invalidity or unenforceability of any provision of this Agreement shall
not affect the validity or enforceability of the other provisions of this
Agreement.
16.6 ENTIRE AGREEMENT AND AMENDMENTS
This Agreement, together with all Exhibits attached hereto, constitutes
the entire agreement between the Parties, and supersedes all prior
agreements, understandings and communications between the Parties, with
respect to the subject matter hereof. No modification or amendment of this
Agreement shall be binding upon the Parties unless in writing and executed
by the duly authorized representative of each of the Parties; this shall
also apply to any change of this clause.
16.7 WAIVERS
The failure by either Party hereto to assert any of its rights hereunder,
including, but not limited to, the right to terminate this Agreement due
to a breach or default by the other Party hereto, shall not be deemed to
constitute a waiver by that Party of its right thereafter to enforce each
and every provision of this Agreement in accordance with its terms.
31
17. PUBLIC ANNOUNCEMENTS
17.1 Except as required by law (including, without limitation, the applicable
disclosure requirements of any relevant regulatory authority or stock
exchange) and as permitted by Section 12.3, neither Party shall make any
public announcement concerning this Agreement, any Contract Product or any
other subject matter hereof without the prior written consent of the other
Party, which shall not be unreasonably withheld or delayed. It shall not
be unreasonable for a Party to withhold consent with respect to any public
announcement containing any of such Party's Confidential Information. In
the event of any required or proposed public announcement, (i) the Parties
shall consult with each other in good faith as to the timing thereof, and
(ii) the Party making such announcement shall provide the other Party with
a copy of the proposed text prior to such announcement sufficiently in
advance of the scheduled release of such announcement to afford such other
Party a reasonable opportunity to review and comment upon the proposed
text. Notwithstanding the foregoing, the Parties agree to prepare a
mutually agreeable press release that may be used by either Party in
connection with this Agreement, and any further announcement containing
substantially the same information may be used without the need to seek
the consent of the other Party. In the case of unintentional public
disclosure concerning this Agreement, any Contract Product or any other
subject matter hereof, the disclosing Party shall promptly inform the
other Party of such disclosure and the other Party shall be entitled to
make a public announcement regarding the subject matter of the disclosure.
The other Party shall notify the disclosing Party of their intention to
make such an announcement.
17.2 Following a Party's consent to or approval of the public announcement of
any information pursuant to this Section 17, both Parties shall be
entitled to make subsequent public announcements of such information
without renewed compliance with this Section 17, unless the scope and/or
duration of such consent or approval is expressly limited.
17.3 Upon conclusion of this Agreement, the Parties will publish a press
release on their future cooperation.
EXHIBITS:
Exhibit 1.6 Description of D-63153
Exhibit 1.28 Zentaris' Know-How
Exhibit 1.29 Zentaris' Patent Rights
Exhibit 8.1 Specifications for Clinical Supplies
[SIGNATURE PAGE FOLLOWS]
32
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed this
12th day of August 2004, by their duly authorized representatives.
Zentaris Spectrum
By: /S/ ▇▇▇▇▇▇ ▇▇▇▇▇ By: /S/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
------------------------- ----------------------------------
Name: Prof. ▇▇. ▇▇▇▇▇▇ ▇▇▇▇▇ Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇, M.D.
Title: Chairman and Title: Chairman, CEO and President
Managing Director
33
EXHIBIT 1.6
[Intentionally Redacted]
D-63153
-------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
34
EXHIBIT 1.28
[Intentionally Redacted]
-------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
35
EXHIBIT 1.29
[Intentionally Redacted]
-------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
36
EXHIBIT 8.1
[Intentionally Redacted]
-------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
37
